← Back to patent-cliff list
(R)-(+)-Rabeprazole sodium
Tier C — Watch / trade(R)-(+)-Rabeprazole sodium
Emcure Pharmaceuticals Ltd
Originator
2007
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Proton pump
Indications (approved)：Gastro-oesophageal reflux disease, Peptic ulcer
Regional status
US
-
EU
-
China
Discontinued
2012-02-14
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of (R)-(+)-Rabeprazole sodium?
Approved indications include: Gastro-oesophageal reflux disease, Peptic ulcer.
When does the (R)-(+)-Rabeprazole sodium patent expire?
No public expiry year is available for (R)-(+)-Rabeprazole sodium yet; this page updates once verified.
How do I get a quote for (R)-(+)-Rabeprazole sodium intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29